Literature DB >> 22475861

Leishmaniasis: vaccine candidates and perspectives.

Bhawana Singh1, Shyam Sundar.   

Abstract

Leishmania is a protozoan parasite and a causative agent of the various clinical forms of leishmaniasis. High cost, resistance and toxic side effects of traditional drugs entail identification and development of therapeutic alternatives. The sound understanding of parasite biology is key for identifying novel drug targets, that can induce the cell mediated immunity (mainly CD4+ and CD8+ IFN-gamma mediated responses) polarized towards a Th1 response. These aspects are important in designing a new vaccine along with the consideration of the candidates with respect to their ability to raise memory response in order to improve the vaccine performance. This review is an effort to identify molecules according to their homology with the host and their ability to be used as potent vaccine candidates. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475861     DOI: 10.1016/j.vaccine.2012.03.068

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Leishmanicidal activity of α-bisabolol from Tunisian chamomile essential oil.

Authors:  Soumaya Hajaji; Ines Sifaoui; Atteneri López-Arencibia; María Reyes-Batlle; Ignacio A Jiménez; Isabel L Bazzocchi; Basilio Valladares; Hafidh Akkari; Jacob Lorenzo-Morales; José E Piñero
Journal:  Parasitol Res       Date:  2018-06-28       Impact factor: 2.289

2.  Perifosine Mechanisms of Action in Leishmania Species.

Authors:  Atteneri López-Arencibia; Carmen Martín-Navarro; Ines Sifaoui; María Reyes-Batlle; Carolina Wagner; Jacob Lorenzo-Morales; Sutherland K Maciver; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  In vitro activities of hexaazatrinaphthylenes against Leishmania spp.

Authors:  Atteneri López-Arencibia; Daniel García-Velázquez; Carmen M Martín-Navarro; Ines Sifaoui; María Reyes-Batlle; Jacob Lorenzo-Morales; Ángel Gutiérrez-Ravelo; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

4.  Identification of metal dithiocarbamates as a novel class of antileishmanial agents.

Authors:  Dhiman Sankar Pal; Dipon Kumar Mondal; Rupak Datta
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

Review 5.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

Review 6.  Novel vaccine approaches for protection against intracellular pathogens.

Authors:  Kristin L Griffiths; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2014-03-06       Impact factor: 7.486

Review 7.  Evaluation of the alum-naloxone adjuvant activity against experimental murine leishmaniasis due to L. major.

Authors:  Arezoo Bozorgomid; Habib Mohammadzadeh Hajipirloo; Khosrow Hazrati Tappeh; Naser Nazari; Seyed Ahmad Karamati; Samira Shirooie
Journal:  J Parasit Dis       Date:  2016-01-13

8.  Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.

Authors:  Eduardo C Roncolato; José E Teixeira; José E Barbosa; Leandra N Zambelli Ramalho; Christopher D Huston
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

9.  Dysfunctional adaptive immunity during parasitic infections.

Authors:  Ryan A Zander; Noah S Butler
Journal:  Curr Immunol Rev       Date:  2013-08-01

Review 10.  Understanding Leishmania parasites through proteomics and implications for the clinic.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Proteomics       Date:  2018-05-02       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.